Alx Oncology Holdings (ALXO) Amortization of Deferred Charges (2020 - 2026)

Alx Oncology Holdings has disclosed Amortization of Deferred Charges across 5 years of filings, most recently posting $68000.0 for Q1 2026.

• Amortization of Deferred Charges for Q1 2026 came in at $68000.0, up 1.49% year-over-year; the trailing twelve-month figure through Mar 2026 was $281000.0 (up 4.85% YoY), and the FY2025 annual result was $280000.0, up 5.66% from the prior year.
• Amortization of Deferred Charges came in at $68000.0 for Q1 2026 at Alx Oncology Holdings, down from $72000.0 in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $72000.0 in Q3 2025 to a low of $61000.0 in Q1 2023.
• The 4-year median for Amortization of Deferred Charges is $66000.0 (2024), against an average of $66384.6.
• Across the five-year window, Amortization of Deferred Charges gained 9.09% in 2025 and rose 1.49% in 2026, its largest moves.
• Alx Oncology Holdings' Amortization of Deferred Charges stood at $64000.0 in 2023, then rose by 7.81% to $69000.0 in 2024, then gained by 4.35% to $72000.0 in 2025, then decreased by 5.56% to $68000.0 in 2026.
• The last three Amortization of Deferred Charges figures came in at $68000.0 (Q1 2026), $72000.0 (Q4 2025), and $72000.0 (Q3 2025), per Business Quant data.